deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT00611858

Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

Phase II Study of Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

Sponsor: Beth Israel Deaconess Medical Center

Conditions Rectal Cancer
Interventions 5-Fluorouracil Cetuximab Radiation
Updated 9 times since 2017 Last updated: Dec 17, 2018 Started: May 31, 2008 Primary completion: Dec 31, 2012 Completion: Sep 30, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow accrual

Other terminated trials from Beth Israel Deaconess Medical Center

See all terminations from Beth Israel Deaconess Medical Center

Other Rectal Cancer trials with similar outcome

Browse all Rectal Cancer trials

Listed as NCT00611858, this PHASE2 trial focuses on Rectal Cancer and remains terminated or withdrawn. Sponsored by Beth Israel Deaconess Medical Center, it has been updated 9 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshotTerminated~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshotTerminated~Feb 2019 – ~Jan 2021 · 23 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  5. Feb 2019 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 4 earlier versions

  1. Dec 2018 — Feb 2019 [monthly]

    Terminated PHASE2

  2. Jun 2018 — Dec 2018 [monthly]

    Terminated PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • Dana-Farber Cancer Institute
  • Massachusetts General Hospital
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations